Clinical Trials Directory

PET/CT and Whole-Body MRI for Detection of Skeletal and Soft Tissue Metastases

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. However, not all cancers are identified reliably due to variable rates of glucose metabolism. Whole-body MRI emerges currently as an excellent modality for morphological characterization of soft tissue and skeletal lesions. Sodium Fluorine-18 (F-18) was used in the 1970's for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The direct comparison of F-18/F-18 FDG PET/CT and whole-body MRI for skeletal metastases detection was not attempted to date. However, such an approach has the potential to improve cancer diagnosis, staging, prognosis, and therapy monitoring. The combination of these technologies may also allow for improved screening or earlier cancer detection. We will attempt a pilot study with 10 patients to acquire the preliminary results needed to proceed with additional 90 subjects.

Stanford is now accepting new patients for this trial. Please contact Andrei Iagaru at 650-725-4711 for more information.



  • procedure : F-18 NaF/F-18 FDG PET/CT
  • procedure : Tc-99m MDP bone scan
  • procedure : Whole-body MRI

Phase: N/A


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Patient is ? 18 years old at the time of the drug administration - Patient provides written informed consent - Patient is diagnosed with ? stage 3 breast cancer or ? stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer - Patient is capable of complying with study procedures - Patient is able to remain still for duration of imaging procedure (about one hour)

External Links

Stanford Medicine Resources:

Footer Links: